Novo Nordisk seeks EU and U.S. approval for new diabetes treatment

News Hour:

Danish Novo Nordisk said on Monday it has filed for the European Union and the U.S. approval of semaglutide to treat adults with type 2 diabetes, reports Reuters.

The company said the results of the clinical trial, which included more than 8,000 adults with type 2 diabetes, demonstrated statistically significant and sustained blood glucose control, and a statistically significant reduction of cardiovascular risk compared to placebo.


This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Song about Bangabandhu to celebrate historic 7th March
The miracle of Hyperbaric Oxygen Therapy (HBOT) and its potential in Bangladesh
Saiful Huq, AAPM’s first Bangladesh-born president
Chinese video app Tik Tok banned in Indonesia for 'inappropriate content'
SINGER Furniture offers up to 60% discount in Bangladesh
Man damages his own brain to forget the Infinity War spoilers he saw before


News of the Month

Scroll Up
%d bloggers like this: